CURRENT STATUS OF GUIDELINES FOR CLINICAL RESEARCH FROM VIEWPOINT OF PHARMACEUTICAL INDUSTRY

被引：4

作者：

DIXON, RB ^{[1
]}

机构：

[1] CIBA GEIGY CORP,SUMMIT,NJ 07901

来源：

关键词：

D O I：

10.1002/j.1552-4604.1977.tb01543.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：691 / 696

页数：6

共 11 条

[1] FDA - GUIDELINES CHISELED IN STONE
DEAN, RL
[J]. SCIENCE, 1970, 169 (3952) : 1264 - &
[2] DEHAEN P, 1976, DRUG COSMET IND, V119, P47
[3] DEHAEN P, 1976, DRUG COSMETIC INDUST, V119, P108
[4] FDA - CLINICALLY MEANINGFUL DATA
FREUND, J
PRESTON, LW
[J]. SCIENCE, 1971, 171 (3969) : 334 - &
[5] KEFAUVER-HARRIS AMENDMENTS OF 1962 - A CRITICAL APPRAISAL OF FIRST 5 YEARS
HOLLISTE.LE
PAGE, IH
PFEIFFER, CC
VISSCHER, MB
[J]. JOURNAL OF CLINICAL PHARMACOLOGY AND NEW DRUGS, 1968, 8 (02): : 69 - &
[6] Hollister L E, 1974, Perspect Biol Med, V17, P243
[7] RESEARCH, REGULATION AND DEVELOPMENT OF NEW PHARMACEUTICALS - PAST, PRESENT AND FUTURE .2.
LASAGNA, L
[J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1972, 263 (02) : 66 - &
[8] MILLER RR, 1975, CLIN PHARMACOL THER, V18, P598
[9] REIFFENSTEIN RJ, 1968, CAN MED ASSOC J, V99, P1134
[10] WARDELL WM, 1973, CLIN PHARMACOL THER, V14, P773